In cancer patients, there is no significant difference in fasting glucose (SMD: −0.402; p-random effects: 0.342), fasting insulin (SMD: 0.107; p-random effects: 0.884), HDL (SMD: −0.185; p-random effects: 0.646), LDL (SMD: 0.211; p-random effects: 0.321), TC (SMD: 0.248; p-random effects: 0.245), TG (SMD: 0.152; p-random effects: 0.638), RR of adverse events (pooled RR: 1.263; p-random effects: 0.75) [67], body mass index (BMI) (WMD: −1.401; p-random effects: 0.797), body weight (WMD: −0.215; p-random effects: 0.922) (Figure 2 and Supplemental Table S1) [65]. This evidence concerns the gene INS and cancer.